Peter Matlock looks forward to applying metabolic profiling to improve the pharmaceutical discovery and development process, develop better nutritional products and enable individualised healthcare
Lipomics Technologies, a privately held company that develops tools for assessing and understanding complex metabolic processes using proprietary technologies for lipid metabolite analysis and interpretation, has announced that Peter Matlock has joined the company as vice president of commercial development.
Apart from business development Matlock also assumes responsibility for Lipomics's marketing effort.
Most recently Matlock was president and director of Bioren, where he was instrumental in moving the company from the concept stage to a productive antibody discovery and optimisation business serving the pharmaceutical industry.
Matlock began his career in business development at Stanford University in 1981 as a licensing associate with responsibilities in licensing research technologies to industry.
Since that time he has worked variously for life-sciences companies such as Creative BioMolecules, Calgene, and Seminis, where he formulated and implemented plans for financing, business development, intellectual property, licensing, contract research and manufacture and product sales starting from basic research technologies.
He was also co-founder of the biotechnology company Viridis, which focused on biocatalysis for pharmaceutical, food and industrial markets, and Applied Phytologics, a molecular farming company for high volume, low-cost manufacturing of recombinant pharmaceutical and industrial proteins.
Among his other achievements was the co-founding of the consulting firm Davis Bioscience Associates, and serving as a senior associate of Context Consulting, where he developed and offered consulting services to clients ranging from start-up businesses to major multinational medical, food and plant biotechnology companies.
"We are very pleased to have Peter join us at Lipomics," said Tom Anderson, CEO.
"His broad and deep experience in helping many life-sciences companies and organisations grow rapidly will help Lipomics's efforts to maintain its position as the leading company in the field of lipid metabolomic research and application.
"His depth of knowledge in managing all the facets of business development will prove invaluable to our continued growth.
"We are most fortunate to have attracted Peter to join our team".
"It's exciting and an honour to be affiliated with Lipomics, which has earned a high level of respect in the industry for its accomplishments," said Peter Matlock.
"I look forward to working with the Lipomics team to open new commercial opportunities and create value for the public by applying metabolic profiling to improve the pharmaceutical discovery and development process, develop better nutritional products and enable individualised healthcare".
Matlock holds an engineer's and master of science degrees in engineering-economic systems - with a focus on advanced technology management - from Stanford University, and a bachelor of arts with honours in economics from Swarthmore College, Pennsylvania.
